Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular events.
The study, “ Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction–associated steatotic liver disease ,” led by researchers from the Radcliffe Department of Medicine at the University of Oxford, highlights a dangerous feedback loop between the liver and the pancreas. In patients with MASLD, the liver often fails to clear insulin from the bloodstream effectively.
This reduced hepatic insulin clearance leads to chronic hyperinsulinemia, which in turn accelerates the progression of liver fibrosis — the most significant predictor of mortality and severe liver outcomes in metabolic patients. Historically, clinical focus has remained largely on insulin resistance and blood glucose levels.
However, this research argues that the absolute level of fasting insulin provides a unique window into liver health.
Emergence of Hyperinsulinemia as a Central Marker in MASLD: Study Design and Core Thesis
The authors propose that elevated fasting insulin—beyond being a consequence of metabolic syndrome—actively contributes to liver fibrosis and predicts major adverse liver and cardiovascular events (MALO and MACE).
The work is led by researchers from the Radcliffe Department of Medicine, University of Oxford.
This impairment sustains chronic hyperinsulinemia, which then accelerates fibrosis progression.
The authors emphasize that insulin clearance failure signals hepatic dysfunction and shifts the disease trajectory from simple steatosis to more advanced tissue damage, situating hyperinsulinemia as a potential driver rather than a secondary feature.
It consolidates existing evidence to argue for the diagnostic and pathophysiological relevance of fasting insulin levels in MASLD, rather than presenting new experimental or cohort data.
The discussion frames fasting insulin as an accessible, non-invasive metric that may reflect hepatic functional status.
The authors discuss how MASLD’s risk profile is entwined with these metabolic conditions.
They contend that this approach could complement existing non-invasive tests and imaging modalities, potentially enhancing risk stratification for cirrhosis and liver failure.
This strengthens the argument for insulin clearance as a therapeutic and diagnostic target.
They speculate that interventions aimed at improving metabolic clearance—potentially including new agents that enhance insulin clearance—could alter disease progression.
The emphasis shifts from glucose-centric management to strategies that directly modulate insulin dynamics.
Incorporating fasting insulin into routine assessment could enrich the diagnostic toolkit and improve the linkage between hepatic fibrosis and metabolic dysfunction, supporting earlier intervention.
Instead, it positions absolute fasting insulin levels as a distinct and informative signal of hepatic function, potentially revealing risk earlier than conventional markers.
Therefore, conclusions about causality and effect sizes remain exploratory and hypothesis-generating rather than definitive.